How has COVID-19 changed PropTech? And how are startups fighting back?

The property industry thrives off the movement and migration of people. With the travel restrictions and lockdowns, PropTech companies have been hard hit. During COVID-19, we have seen PropTech companies make redundancies and cuts as their businesses have significantly reduced. However, we are also seeing some companies continue to accelerate their growth. Here, I explore…

This content is for members only. Visit the site and log in/register to read.

The post How has COVID-19 changed PropTech? And how are startups fighting back? first appeared on EU-Startups.

EU-Startups

New COVID-19 modelling numbers should be a wake-up call for Canadians: expert – Yahoo News Canada

New COVID-19 modelling numbers should be a wake-up call for Canadians: expert  Yahoo News Canada
“sweden startups when:7d” – Google News

Thinking outside the box: Denver startup offers Covid-19 solutions with shipping containers – 9News.com KUSA

Thinking outside the box: Denver startup offers Covid-19 solutions with shipping containers  9News.com KUSA
“startups when:1d” – Google News

[enVerid in PR Newswire] Open-Source enVerid COVID-19 Energy Estimator Available for Building Engineers

enVerid Systems, a leading provider of indoor air quality solutions, today shared a new tool to calculate energy, costs and carbon impact of various HVAC strategies for mitigating airborne transmission of COVID-19. The free, open-source enVerid COVID-19 Energy Estimator allows building owners, mechanical engineers, and facility managers to quickly gain a more complete picture of the risk, costs, and carbon impacts of different ventilation and filtration approaches. The enVerid COVID-19 Energy Estimator is informed by enVerid’s decade-long focus on indoor air quality (IAQ) and energy efficiency.

Read more here.

The post [enVerid in PR Newswire] Open-Source enVerid COVID-19 Energy Estimator Available for Building Engineers appeared first on OurCrowd Blog.

OurCrowd Blog

Quarantines? Social distancing? In the COVID-19 era, Israeli Industry 4.0 startups find creative ways to install their technologies remotely – CTech

Quarantines? Social distancing? In the COVID-19 era, Israeli Industry 4.0 startups find creative ways to install their technologies remotely  CTech
“startups when:1d” – Google News

Resilience raises over $800 million to transform pharmaceutical manufacturing in response to COVID-19

Resilience, a new biopharmaceutical company backed by $ 800 million in financing from investors including ARCH Venture Partners and 8VC, has emerged from stealth to transform the way that drugs and therapies are manufactured in the U.S.

Founded by ARCH Venture Partners investor Robert Nelsen, National Resilience Inc., which does business as Resilience, was born out of Nelsen’s frustrations with the inept American response to the COVID-19 pandemic.

According to a statement, the company will invest heavily in developing new manufacturing technologies across cell and gene therapies, viral vectors, vaccines and proteins.

Resilience’s founders identified problems in the therapeutic manufacturing process as one of the key problems that the industry faces in bringing new treatments to market — and that hurdle is exactly what the company was founded to overcome.

“COVID-19 has exposed critical vulnerabilities in medical supply chains, and today’s manufacturing can’t keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale. We are committed to tackling these huge problems with a whole new business model,” said Nelsen in a statement.

The company brings together some of the leading investment firms in healthcare and biosciences, including operating partners from Flagship Pioneering like Rahul Singhvi, who will serve as the company’s chief executive; former Food and Drug Administration commissioner Scott Gottlieb, a partner at New Enterprise Associates and director on the Resilience board; and Patrick Yang, the former executive vice president and global head of technical operations at Roche/Genentech .

“It is critical that we adopt solutions that will protect the manufacturing supply chain, and provide more certainty around drug development and the ability to scale up the manufacturing of safe, effective but also more complex products that science is making possible,” said Dr. Gottlieb, in a statement. “RESILIENCE will enable these solutions by combining cutting edge technology, an unrivaled pool of talent, and the industry’s first shared service business model. Similar to Amazon Web Services, RESILIENCE will empower drug developers with the tools to more fully align discovery, development, and manufacturing; while offering new opportunities to invest in downstream innovations in formulation and manufacturing earlier, while products are still being conceived and developed.”

Other heavy hitters in the world of medicine and biotechnology who are working with the company include Frances Arnold, the Nobel Prize-winning professor from the California Institute of Technology; George Barrett, the former chief executive of Cardinal Health; Susan Desmond-Hellmann, the former president of product development at Genentech; Kaye Foster, the former vice president of human resources at Johnson and Johnson; and Denice Torres, the former president of Johnson & Johnson Pharmaceutical and Consumer Companies.

Startups – TechCrunch